JSPR (Jasper Therapeutics) EBITDA Margin %: 0.00% (As of Mar. 2026)


JSPR Jasper Therapeutics Inc JSPR
29 GF Score
Price $0.47
! 1 Warning Sign
View Full Analysis

What is Jasper Therapeutics EBITDA Margin %?

Jasper Therapeutics JSPR +11.14% 29 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates JSPR with a GF Score™ of 29/100. The stock has 1 warning sign investors should review. Among 941 Biotechnology companies, Jasper Therapeutics ranks worse than 106269.82% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Jasper Therapeutics's EBITDA for the three months ended in Mar. 2026 was $-10.93 Mil. Jasper Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Jasper Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.

Jasper Therapeutics  (NAS:JSPR) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Jasper Therapeutics EBITDA Margin % Related Terms

Jasper Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Jasper Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jasper Therapeutics EBITDA Margin % Chart

Jasper Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Jasper Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

JSPR vs CVKD, BRTX, APRE: EBITDA Margin % Comparison

For the Biotechnology subindustry, Jasper Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Jasper Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jasper Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Jasper Therapeutics's EBITDA Margin % falls into.


JSPR
29GF Score
Jasper Therapeutics Inc JSPR
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jasper Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Jasper Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-82.827/0
= %

Jasper Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-10.931/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Jasper Therapeutics (JSPR) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jasper Therapeutics and its competitors. According to the industry distribution chart, Jasper Therapeutics ranks #999999 out of 941 companies in the Biotechnology industry.
Is Jasper Therapeutics' EBITDA Margin % too high?
Jasper Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, Jasper Therapeutics ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jasper Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Jasper Therapeutics' EBITDA Margin % compare to CVKD and BRTX?
According to the Biotechnology industry distribution chart, Jasper Therapeutics ranks #999999 out of 941 companies for EBITDA Margin %. This places Jasper Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jasper Therapeutics and its competitors. Jasper Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jasper Therapeutics stock overvalued right now?
Jasper Therapeutics (JSPR) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Jasper Therapeutics' overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jasper Therapeutics (JSPR), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jasper Therapeutics Business Description

Address 2200 Bridge Parkway, Suite 102, Redwood, CA, USA, 94065
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
29GF Score

Get the complete analysis for JSPR

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.47
Price